Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.

Transl Oncol · 2019 · PMC6517847 · PMID 31082584

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

There was a nonsignificant trend towards weight loss at day 21 in the URML-3881 + cisplatin group that improved weekly thereafter.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.